Filter posts

ICYMI: Drug Development is Complicated. Let’s Start with the Facts.

Here’s a fact you might not have known: 90% of drug development programs fail. Yet …

BIO Expands Cooperation with China-Based Pharma Group

Earlier this week BIO signed of a Memorandum of Understanding for Cooperation with the Pharmaceutical Association …

Discover Trends and Investment Opportunities at the BIO Investor Forum

The 2015 BIO Investor Forum in San Francisco is shaping up to be a must-attend event …

Our Health Care Ecosystem

There are currently 907 drugs and vaccines targeting more than 100 diseases in development by …

It Takes a Village: The New Pharma-VC Model for Biotech Investing

High-profile funding collaborations between pharmaceutical companies and traditional venture capital funds have made headlines in …

What Will It Take for the U.S. to Maintain Leadership in the Biopharma Industry?

The biopharmaceutical industry is an important contributor to U.S. economic growth and sustainability, with more …

Fireside Chat with Moncef Slaoui, GlaxoSmithKline

Moncel Slaoui, chairman of research and development (R&D) at GlaxoSmithKline (GSK), opened the 2012 BIO …

Managing in a Cost-Constrained Environment

By Jill E. Sackman, D.V.M., Ph.D., Senior Consultant, and Matt Levy, J.D., Business Analyst, at …

Biopharma Industry Enthusiastic About 2012

By Eric S. Langer, president and managing partner, BioPlan Associates, Inc. 2012 Annual Study shows budgets, …

2011 BIO International event spotlights expert feedback on regulatory strategy

Our good friend John Carroll, blogs on the free ranging discussion he will be hosting …